Revvity vs Medtronic

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (94 vs 90)
Revvity logo

Revvity

LeaderHealthcare Tech

Life Science Tools & Diagnostics

Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.

AI VisibilityBeta
Overall Score
A94
Category Rank
#1 of 1
AI Consensus
72%
Trend
up
Per Platform
ChatGPT
92
Perplexity
99
Gemini
96

About

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.

Full profile
Medtronic logo

Medtronic

LeaderHealthcare Tech

Enterprise

World's largest medical device company with $32.4B FY2024 revenue; Hugo robotic surgery challenges Intuitive Surgical; MiniMed automated insulin system; Patient Monitoring spin-off 2024; NYSE: MDT.

AI VisibilityBeta
Overall Score
A90
Category Rank
#126 of 290
AI Consensus
53%
Trend
up
Per Platform
ChatGPT
85
Perplexity
97
Gemini
99

About

Medtronic plc is the world's largest medical device company, founded in 1949 by Earl Bakken and Palmer Hermundslie in a Minneapolis, Minnesota garage—where Bakken invented the first wearable external pacemaker—and now incorporated in Ireland with operational headquarters in Dublin, trading on NYSE (MDT). The company generated approximately $32.4 billion in revenues for fiscal year 2024 (ending April 26, 2024) under CEO Geoff Martha, spanning cardiovascular, neuroscience, surgical, and diabetes therapy technologies. Medtronic's 2015 acquisition of Covidien for $49.9 billion—at the time the largest medical device merger in history—added surgical instruments, patient monitoring, and respiratory interventions while enabling Irish incorporation that reduced the company's effective tax rate. In 2024, Medtronic announced the spin-off of its Patient Monitoring & Respiratory Interventions segment as an independent company (NewCo), sharpening focus on higher-margin, high-growth therapy areas.

Full profile

AI Visibility Head-to-Head

94
Overall Score
90
#1
Category Rank
#126
72
AI Consensus
53
up
Trend
up
92
ChatGPT
85
99
Perplexity
97
96
Gemini
99
89
Claude
97
88
Grok
82

Key Details

Category
Life Science Tools & Diagnostics
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Revvity
Life Science Tools & Diagnostics

Integrations

Only Revvity
Only Medtronic
Revvity is classified as company. Medtronic is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.